5.72
-0.03 (-0.52%)
Penutupan Terdahulu | 5.75 |
Buka | 5.92 |
Jumlah Dagangan | 2,977,608 |
Purata Dagangan (3B) | 1,602,645 |
Modal Pasaran | 307,890,432 |
Harga / Jualan (P/S) | 2.47 |
Harga / Buku (P/B) | 0.780 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
Margin Keuntungan | -79.94% |
Margin Operasi (TTM) | -2,318.99% |
EPS Cair (TTM) | -2.05 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 5,556.00% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 2.33% |
Nisbah Semasa (MRQ) | 9.00 |
Aliran Tunai Operasi (OCF TTM) | -130.36 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.38 M |
Pulangan Atas Aset (ROA TTM) | -15.49% |
Pulangan Atas Ekuiti (ROE TTM) | -23.46% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Prothena Corporation plc | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -0.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | 0.50 |
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 18.99% |
% Dimiliki oleh Institusi | 73.95% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 81.00 (Piper Sandler, 1,316.08%) | Beli |
Median | 18.00 (214.69%) | |
Rendah | 4.00 (B of A Securities, -30.07%) | Jual |
Purata | 29.20 (410.49%) | |
Jumlah | 4 Beli, 1 Jual | |
Harga Purata @ Panggilan | 4.58 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
B of A Securities | 28 May 2025 | 4.00 (-30.07%) | Jual | 4.60 |
Chardan Capital | 27 May 2025 | 18.00 (214.69%) | Beli | 4.58 |
09 May 2025 | 40.00 (599.30%) | Beli | 7.43 | |
HC Wainwright & Co. | 27 May 2025 | 14.00 (144.76%) | Beli | 4.58 |
09 May 2025 | 30.00 (424.48%) | Beli | 7.43 | |
JMP Securities | 27 May 2025 | 29.00 (406.99%) | Beli | 4.58 |
09 May 2025 | 78.00 (1,263.64%) | Beli | 7.43 | |
Piper Sandler | 27 May 2025 | 81.00 (1,316.08%) | Beli | 4.58 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
18 Jun 2025 | Pengumuman | Prothena Announces Corporate Restructuring |
16 Jun 2025 | Pengumuman | Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease |
08 May 2025 | Pengumuman | Prothena Reports First Quarter 2025 Financial Results and Business Highlights |
01 May 2025 | Pengumuman | Prothena to Report First Quarter 2025 Financial Results on May 8 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |